Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor by Gharanei, M. et al.
 
Attenuation of doxorubicin-induced 
cardiotoxicity by mdivi-1: a 
mitochondrial division/mitophagy 
inhibitor  
Gharanei, M. , Hussain, A. , Janneh, O. and Maddock, H.L. 
 
Published version deposited in CURVE October 2013 
 
Original citation & hyperlink:  
Gharanei, M. , Hussain, A. , Janneh, O. and Maddock, H.L. (2013) Attenuation of doxorubicin-
induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. PLoS ONE, 
volume 8 (10): e77713. 
http://dx.doi.org/10.1371/journal.pone.0077713 
 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original 
author and source are credited.  
 
 
 
 
 
CURVE is the Institutional Repository for Coventry University 
http://curve.coventry.ac.uk/open  
Attenuation of Doxorubicin-Induced Cardiotoxicity by
mdivi-1: A Mitochondrial Division/Mitophagy Inhibitor
Mayel Gharanei1, Afthab Hussain1, Omar Janneh1,2, Helen Maddock1*
1 Department of Biomolecular and Sport Sciences, Coventry University, Coventry, United Kingdom, 2 Division of Biomedical Sciences, St. George's, University
of London, London, United Kingdom
Abstract
Doxorubicin is one of the most effective anti-cancer agents. However, its use is associated with adverse cardiac
effects, including cardiomyopathy and progressive heart failure. Given the multiple beneficial effects of the
mitochondrial division inhibitor (mdivi-1) in a variety of pathological conditions including heart failure and ischaemia
and reperfusion injury, we investigated the effects of mdivi-1 on doxorubicin-induced cardiac dysfunction in naïve and
stressed conditions using Langendorff perfused heart models and a model of oxidative stress was used to assess the
effects of drug treatments on the mitochondrial depolarisation and hypercontracture of cardiac myocytes. Western
blot analysis was used to measure the levels of p-Akt and p-Erk 1/2 and flow cytometry analysis was used to
measure the levels p-Drp1 and p-p53 upon drug treatment. The HL60 leukaemia cell line was used to evaluate the
effects of pharmacological inhibition of mitochondrial division on the cytotoxicity of doxorubicin in a cancer cell line.
Doxorubicin caused a significant impairment of cardiac function and increased the infarct size to risk ratio in both
naïve conditions and during ischaemia/reperfusion injury. Interestingly, co-treatment of doxorubicin with mdivi-1
attenuated these detrimental effects of doxorubicin. Doxorubicin also caused a reduction in the time taken to
depolarisation and hypercontracture of cardiac myocytes, which were reversed with mdivi-1. Finally, doxorubicin
caused a significant elevation in the levels of signalling proteins p-Akt, p-Erk 1/2, p-Drp1 and p-p53. Co-incubation of
mdivi-1 with doxorubicin did not reduce the cytotoxicity of doxorubicin against HL-60 cells. These data suggest that
the inhibition of mitochondrial fission protects the heart against doxorubicin-induced cardiac injury and identify
mitochondrial fission as a new therapeutic target in ameliorating doxorubicin-induced cardiotoxicity without affecting
its anti-cancer properties.
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Introduction
The anthracycline antibiotic doxorubicin is used to treat a
wide variety of cancers, but reports of its cardiotoxic properties
compromises its clinical utility [1–3]. The cardiotoxic effects of
doxorubicin are thought to be mediated via disruption of the
mitochondrial function [4]. Previous studies have also shown
doxorubicin to cause cardiotoxicity through the generation of
free radicals [5], stimulation of lipid peroxidation [6] and
alteration and disruption of cellular membrane integrity [7].
Arrhythmias, hypotension and depression of the contractile
function are some of the acute effects of doxorubicin-induced
cardiotoxicity [8], while chronic heart failure and dilative
cardiomyopathy are more common and severe in patients who
are on long term anthracyclines treatment [9,10]. Large scale
clinical trials have shown that doxorubicin induced
cardiotoxicity is irreversible and dose dependent [11].
Due to advances in basic and clinical cancer research,
cancer and malignancies are becoming more manageable,
unfortunately the adverse cardiovascular effects of systemic
anticancer agents are still a serious concern [12,13]. Thus it is
imperative to understand the cellular and molecular basis of
doxorubicin-induced cardiotoxicity with the view to finding
therapies that would offer cardioprotection without affecting its
anti-tumour effects. Interventions using β blockers, free radical
scavengers, antioxidants and renin-angiotensin system
inhibitors have met with limited success due, not only, to side
effects but also because of their negative interactions with
doxorubicin [14]. While aiming to reduce the cardiotoxic effects
of anthracyclines using adjunct therapies, it is imperative to
assess the effects in cancer cell line to ascertain the clinical
utility of such treatments. Interestingly, recent studies using the
phosphodiesterase-5 inhibitors sildenafil or tadalafil have
shown promise by showing a reduction in the cardiotoxic
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effects of doxorubicin without affecting its anti-cancer activity
[15,16].
Cell death pathways activated by doxorubicin treatment
usually involve the mitochondria to initiate apoptosis or
necrosis [17,18]. Mitochondrial dynamics are found to play an
essential role in cellular function and apoptosis [19]. In order to
maintain mitochondrial integrity and efficiency, a constant
interplay between mitochondrial fission and fusion is important.
Previous studies have demonstrated that upon induction of
oxidative stress or ischaemia, dynamin related protein 1 (Drp1),
a protein involved in mitochondrial fission, translocates from
the cytosol to the mitochondria to execute the mitochondrial
division process [20]. This involves hydrolysing GTP [21–23],
which dysregulates the balance between mitochondrial fusion
and fission. Mitochondrial fission leads to cytochrome c release
and activation of caspases, which can ultimately lead to cell
death [20,24,25]. Studies also reported that the dominant
negative form of Drp1, DrpK38A, had the ability to inhibit
mitochondrial division [20] suggesting a regulatory role for Drp1
in mitochondria-mediated apoptosis. Additionally, inhibition of
mitochondrial division either genetically or pharmacologically
with the mitochondrial division inhibitor 1 (mdivi-1) has been
found to inhibit cell death in models of ceramide-induced
toxicity [17] and myocardial ischaemia and reperfusion injury
[26]. Furthermore, it was recently shown that treatment with
mdivi-1 protected against pressure induced heart failure by
ameliorating left ventricular dysfunction and promoting
angiogenesis [27]. Increase in apoptosis and abnormal
mitophagy noticed in pressure overload samples were also
prevented when treated with mdivi-1 [27].
Cancers are likely to develop in the later stages of life, when
the chances of developing heart diseases are equally high [28].
Patients with pre-existing heart diseases are usually excluded
or underrepresented in clinical trials, which aim to identify the
efficacy and potential adverse effects of drugs. We have
recently shown that doxorubicin administration at reperfusion
exacerbates ischaemia reperfusion injury, which was prevented
when co-administered with cyclosporin A [29]. It is therefore
necessary to investigate the off-target effects of anti-cancer
therapeutics or adjunct therapies in stressed or diseased
conditions such as ischaemia and reperfusion injury.
Given that doxorubicin-induced cardiotoxicity may be
mediated by an imbalance in mitochondrial fusion and fission,
we investigated the effects mdivi-1 on doxorubicin-induced
cardiotoxicity using the Langendorff model in naïve and in
conditions of ischaemia and reperfusion injury. A model of
oxidative stress was used to record the time taken to
depolarisation and hypercontracture of cardiac myocytes upon
drug treatment and western blot analysis was used to evaluate
the levels signalling proteins. Data on the effects of mdivi-1 on
the cytotoxicity of doxorubicin was also assessed in HL60 cell
line.
Methods
Chemicals
Doxorubicin hydrochloride and mdivi-1 were purchased from
Tocris Cookson (Bristol, UK). Mdivi-1 was dissolved in DMSO,
ensuring that the final concentration of DMSO was less than
0.01% during the experiments. Doxorubicin was dissolved in
ultra-pure water. The dissolved drugs were aliquotted and
stored at -20°C. All other reagents unless otherwise stated
were obtained from Fisher Scientific (UK). All western blot
reagents were purchased from Bio-Rad, UK. Antibodies were
from New England Biolabs, UK.
Animals
Male Sprague-Dawley rats (350-400g body weight) were
used in all experiments. Experiments were conducted in
accordance with the guidelines on the operation of animals
(Scientific Procedures Act 1986) and approved by the Coventry
University biological resource animal welfare and ethics
committee. Animals were obtained from Charles River UK
Limited (Margate, UK) and kept in standard laboratory cages at
Coventry University.
Isolated perfused heart preparation
Rats were sacrificed by schedule one method of cervical
dislocation and the hearts were rapidly excised and placed into
ice-cold Krebs Henseleit (KH) buffer. The hearts were quickly
mounted onto the Langendorff system and retrogradely
perfused with KH buffer (118.5mM NaCl, 25mM NaHCO3,
4.8mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 1.7mM CaCl2, and
12mM glucose, pH 7.4). KH buffer was gassed using 95% O2
and 5% CO2 and maintained at 37°C at all times. The left
atrium was trimmed away and a latex iso-volumic balloon was
carefully introduced into the left ventricle and inflated up to
5-10mmHg. Functional recordings were taken via a
physiological pressure transducer connected to Powerlab (AD
Instruments Ltd. Chalgrove, UK). Left ventricular pressure,
heart rate and coronary flow were measured at regular
intervals. The hearts used for the naïve experiments were
weighed and frozen at the end of the experimental protocol.
To simulate ischaemia and reperfusion protocol a snare was
used to tighten to left descending coronary artery to induce
ischaemia and release of the snare initiated reperfusion. At the
end of reperfusion ± drug treatment the snare was tightened to
re-occlude the coronary artery branch. A 1ml solution of 0.25%
Evans blue was then infused slowly via the aorta to delineate
the non-risk zone of the myocardium, which stained dark blue.
The hearts were weighed and frozen at -20°C until used. The
frozen hearts were then sliced into 2mm thick transverse
sections and incubated in triphenyltetrazolium chloride (TTC)
solution (1% in phosphate buffer) at 37°C for 10 - 12 min and
fixed in 10% formalin for at least 4 hours. The tissue at risk
stained red and infarct tissue appeared pale. The risk zone and
infarct areas were traced onto acetate sheets. Using
computerised planimetry (Summasketch II, Summagraphics),
the percentage of infarct to risk ratio (%) was calculated.
Langendorff protocol
All hearts were allowed to stabilise for 20 minutes prior to
being subjected to vehicle or drug treatment for 120 minutes
(normoxic protocol) or 35 minutes regional ischaemia followed
by 120 minutes reperfusion ± drug treatment (IR protocol). The
hearts were randomly assigned to the following groups; 1)
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normoxic protocol: a) hearts perfused with KH buffer (control)
for 140 minutes; b) hearts perfused with doxorubicin (1µM) for
120 minutes following 20 minutes of stabilisation; c) hearts
perfused with mdivi-1 (1µM) for 120 minutes following 20
minutes of stabilisation and, d) hearts perfused with
doxorubicin (1µM) in presence of mdivi-1 (1µM) for 120
minutes following the stabilisation period. 2) Or hearts
underwent an ischaemia/reperfusion protocol: e) Perfusion with
KH buffer alone for 120 minutes following 20 minutes of
stabilisation and 35 minutes of regional ischaemia; f) hearts
perfused with doxorubicin (1µM) throughout the duration of
reperfusion; g) hearts perfused with mdivi-1 (1µM) throughout
the duration of reperfusion and, h) hearts perfused with
doxorubicin (1µM) in presence of mdivi-1 (1µM) throughout the
duration of reperfusion (Figure 1).
Isolation of adult rat cardiac myocytes
Adult rat cardiac myocytes were isolated by enzymatic
digestion, as described previously [30]. Briefly, male Sprague
Dawley rats (350-400g body weight) were sacrificed by cervical
dislocation and the hearts were quickly excised and mounted
on a modified Langendorff apparatus. Then the hearts were
perfused with modified KH bicarbonate buffer (116mM NaCl,
25.0mM NaHCO3, 5.4mM KCl, 0.4mM MgSO4 .7.H2O, 1.7mM
CaCl2, 10mM glucose, 20mM taurine, 5mM pyruvate and
0.9mM Na2HPO4.12H2O, pH 7.4). The buffer was oxygenated
with 95% O2 and 5% CO2; 37°C. Hearts were perfused for 5
minutes with calcium free KH buffer, upon perfusion with the
calcium free buffer the heart ceased contraction. The hearts
underwent a final 5 minute perfusion cycle with modified KH
digestion buffer (0.075% Worthington’s Type II Collagenase,
4.4μM CaCl2, pH 7.4). During perfusion with collagenase the
effluent was collected and reused.
After perfusion with collagenase the heart was removed and
the atria were cut away. The ventricles were teased apart and
incubated with fresh KH digestion buffer for 10 minutes on an
orbital shaker. The digestion buffer was aspirated and passed
through a nylon mesh and the filtrate was collected and
centrifuged at 400 rpm for 2 minutes. The supernatants were
removed using a sterile pipette and the pellet was redistributed
Figure 1.  Treatment protocol for the naïve and ischaemia/reperfusion Langendorff studies.  Naïve: 20 minutes of stabilisation
followed by 120 minutes of drug treatments or treatment with vehicle control. Ischaemia/reperfusion: 20 minutes stabilisation, 35
minutes ischaemia and 120 minutes of reperfusion ± drug treatments.
doi: 10.1371/journal.pone.0077713.g001
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in 15ml freshly prepared restoration buffer (116mM NaCl,
25.0mM NaHCO3, 5.4mM KCl, 0.4mM MgSO4 .7.H2O, 10mM
glucose, 20mM taurine, 5mM pyruvate 0.9mM
Na2HPO4.12H2O, 1% BSA and 1% Pen-Strep, pH 7.4). The
calcium concentration was gradually brought to 1.25 mM to
avoid calcium overload. The isolated myocytes were incubated
at 37 °C, 5% CO2, for 24 hours before being used for protocol
to assess depolarisation and hypercontraction of cardiac
myocytes.
Protocol for oxidative stress induced depolarisation
and hypercontraction
Oxidative stress in response to the positively charged
fluorescent dye, tetramethylrhodamine methyl ester (TMRM)
and laser illumination was used to record the time taken to
depolarisation and hypercontraction of cardiac myocytes [31].
Briefly, TMRM was used as it penetrates and concentrates in
negatively charged mitochondria due to its charged nature.
Laser illumination causes the TMRM to release ROS from the
mitochondria, leading to depolarisation of the mitochondrial
membrane. The release of TMRM along with the content of the
mitochondria into the cytoplasm can be observed as an
increase in fluorescence intensity on the confocal microscope.
Oxidative stress was continued until the cells underwent
hypercontracture, marking the point of ATP depletion and cell
death. The time taken to depolarisation and hypercontracture
were recorded.
Following the overnight incubation of the isolated cardiac
myocytes, the cells were transferred to laminin-coated cover
slips and allowed to adhere for 3 hours prior to being prepared
for drug treatment and microscopy. The adherent cardiac
myocytes were then incubated for 15 minutes in microscopy
buffer (KH buffer supplemented with 10 mM HEPES and 1.2µM
CaCl2, pH 7.4) containing 3µM TMRM. The TMRM was then
washed away and the cells were incubated without or with the
drugs for 10 minutes before being placed on the confocal
microscope.
Cells were assigned to the following groups: Control group,
incubated with microscopy buffer alone for 10 minutes;
incubation with 1µM doxorubicin and in presence of mdivi-1
(1µM) or incubation with mdivi-1 (1µM) alone.
Confocal microscope
The cover-slips including the adherent myocytes were placed
on the heated stage (37°C) on a Zeiss 510 CLSM confocal
microscope equipped with 20x objective lens (NA 1.3). 543-nm
emission line of HeNe laser was used to initiate oxidative
stress. A 585-nm long pass filter was used to collect TMRM
fluorescence. All confocal settings were kept constant
throughout the experiments to ensure comparability. Images
were analysed using Zeiss software (LSM 2.8)
Assessment of HL60 cells viability
HL60 cells (10,000 cells/well) were incubated in the
presence and absence of the drugs (alone and in combination)
in a 96 well microtitre plate for 24h. After 24h, 20µl of 5mg/ml
MTT was added to each well and incubated for 2h. Thereafter,
100µl of lysis buffer (containing 15% SDS in 50% dimethyl
formamide) was added to each well and incubated overnight
before the absorbance was read at 492nm. Data was analysed
and the background absorbance was subtracted from the
values obtained, which were then normalised against control.
Western blot analysis
Approximately 50 mg of the frozen heart sample was used
for protein extraction by homogenizing the samples in
suspension buffer (100mM NaCl, 10mM TRIS, 1mM
ethylenediaminetetraacetic acid, (pH 8.0), 2mM Sodium
Pyrophosphate, 2mM Sodium Fluoride, 2mM ß-
Glycerophosphate and protease inhibitor cocktail followed by
high speed centrifugation. The supernatants were assessed for
protein content using nanoDrop spectrophotometer ND1000
(Thermo Scientific). Then 60µg of the protein was loaded into
the wells of the precast gels 4-12% (Bio-Rad, UK) and
separated at 130mV for 90minutes. After separation, the
proteins were transferred to The Hybond-P Polyvinyl Difluoride
membrane (PVDF) using Trans-Blot Turbo Transfer system
(Bio-Rad) and probed for the phosphorylated and total form of
Akt (Ser473) and Erk 1/2 (Thr202/Thr204). The relative changes in
the phosphorylated Akt and Erk 1/2 protein levels were
measured and corrected for differences in protein loading as
established by probing for total Akt and Erk 1/2 respectively.
Flow cytometric analysis
Following the isolation of adult ventricular myocytes, the cells
were incubated in the absence or the presence of doxorubicin
(1µM), mdivi-1 (1µM) and the combination of doxorubicin and
mdivi-1 in an atmosphere of 37 °C, 21 % O2 and 5 % CO2 for 4
hours. Following the drug treatment period, the cells were
harvested into labelled eppendorff tubes and centrifuged at
1200 rpm for 2 minutes. The cells were then resuspended in
phosphate buffered saline (PBS) and fixed with 3%
formaldehyde for 10 minutes at room temperature. Finally, the
cells were permeabilised by incubation with ice-cold 90%
methanol for 30 minutes at 4 °C followed by freezing the
samples at -20 °C to be analysed the following day.
The following day, the cells were washed 2x with incubation
buffer (0.5 % BSA in PBS) followed by blocking with the
incubation buffer at room temperature for 10 minutes. The cells
were then probed with the primary anti-body (phospho-Drp1
and phospho-p53) at 1:500 dilutions in incubation buffer at
room temperature for 1 hour. The cells were washed 2x with
the incubation buffer and resuspended in alexa flour@
conjugated secondary antibody at 1:1000 dilution for 30
minutes at room temperature. Following the final 2x washes
with the incubation buffer, the cells were resuspended in PBS
and analysed with the flow cytometer on the FL1 channel.
Statistical analysis
The data were expressed as mean ± SEM. Infarct size, the
times taken to depolarisation and hypercontracture and the
western blot data were tested for group differences using one
way analysis of variance (ANOVA) with Fishers post hoc tests.
Left ventricular developed pressure, heart rate and coronary
flow were assessed for statistical difference using one-way
Doxorubicin-Induced Mitochondrial Fission
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analysis of variance (ANOVA) for each time point. A p-value of
p<0.05 was considered statistically significant.
Results
Mdivi-1 protects against doxorubicin induced
myocardial dysfunction and infarction in naïve
conditions
The effects of doxorubicin (alone and in combination with
mdivi-1) on LVDP recording is demonstrated in Figure 2a. We
observed that doxorubicin caused a significant (p<0.05 vs. time
matched control) drop in LVDP after 90 minutes of drug
treatment (at 120 minutes of treatment; 45.1 ± 4.7% vs. 71.6 ±
6.1%, respectively, p<0.05, Figure 2a) which was attenuated by
co-administration with mdivi-1 (at 120 minutes; 45.1 ± 4.7% vs.
65.1 ± 11.4%, respectively, p<0.05, Figure 2a). Treatment with
mdivi-1 alone did not appear to have a significant effect on
LVDP as compared to control (66.9 ± 7 % vs. 71.6 ± 6.1%,
respectively, Figure 2a).
Doxorubicin treatment caused a significant reduction in the
heart rate as compared to time matched controls (at 120
minutes; 68.6 ± 1.7% vs. 105.7 ± 10.3%, respectively, p<0.01;
Figure 2b). Figure 2b also shows that co-administration of
doxorubicin with mdivi-1 significantly reversed the effects of
doxorubicin alone on heart rate (at 120 minutes; 88.6 ± 3% vs.
68.6 ± 1.7%, respectively, p<0.05, Figure 2b), while mdivi-1
alone did not have an effect on heart rate when compared to
control (97.9 ± 7% vs. 105.7 ± 10.3%, respectively, Figure 2b).
Doxorubicin treatment also caused a significant reduction
(p<0.05) in the coronary flow after 75 minutes of treatment as
compared to time matched control values (at 120 minutes; 36 ±
7.3% vs. 79.6 ± 10%, respectively, p<0.05, Figure 2c), which
was attenuated when doxorubicin was co-administered with
mdivi-1 (at 120 minutes; 36 ± 7.3% vs.73.9 ± 10.8%,
respectively, p<0.05, Figure 2c), while mdivi-1 alone did not
have an effect when compared to control (64.9 ± 8% vs. 79.6 ±
10%, respectively, Figure 2c) .
Figure 3 shows the effects of doxorubicin (alone and in
combination with mdivi-1) on infarct to risk ratio in the naïve
Langendorff hearts. Doxorubicin (1µM) caused a significant
(p<0.001) increase in the infarct size in the left ventricle as
compared to control (29.74 ± 4.2% vs. 10.6 ± 1.34%,
respectively, Figure 3) which was significantly (p<0.05)
reversed (29.74 ±4.2% vs. 15.4 ±1.4 %, respectively, Figure 3)
by mdivi-1 co-administration.
Mdivi-1 protects against doxorubicin-induced
cardiotoxicity in the conditions of ischaemia/
reperfusion injury
Haemodynamic data recorded for tested agents in the
presence of ischaemia/reperfusion injury is presented in Figure
4. We observed no significant difference for the heart rate
values recorded from all the treatment groups (Figure 4a).
Doxorubicin treatment during the reperfusion caused a
significant reduction in the LVDP as compared to time-matched
control from 45 minutes into reperfusion (at 120 minutes of
treatment; 47.3 ± 3% vs. 76.3 ± 8.6%, respectively, p<0.05,
Figure 4b). Co-treatment with mdivi-1 attenuated the reduction
in LVDP observed with doxorubicin alone (at 120 minutes of
treatment; 70.3 ± 13.5% vs. 47.3 ± 3%, respectively, p<0.05,
Figure 4b). As observed in the naïve study, doxorubicin
treatment also caused a significant reduction in the coronary
flow following ischaemia/reperfusion injury as compared to
time-matched controls (at 120 minutes; 32 ± 3.2% vs. 49.1 ±
6.2%, respectively, p<0.05), which was significantly reversed
by co-treatment with mdivi-1 (at 120 minutes; 32 ± 3.2% vs.
53.3 ± 14. 8%, respectively, p<0.05, Figure 4c). Doxorubicin
treatment during the reperfusion phase significantly increased
(P<0.01) infarct size to risk ratio as compared to vehicle control
(69.4 ± 7% vs. 47.4 ± 2.5%, respectively, Figure 5). Treatment
with mdivi-1 alone during the reperfusion phase significantly
reduced infarction caused during reperfusion injury as
compared to control (32.2 ± 1.6% vs. 47.4 ± 2.5%, respectively,
p<0.01, Figure 5). Additionally, treatment with mdivi-1 also
attenuated the exacerbation of the ischaemia/reperfusion injury
caused by doxorubicin treatment as compared to doxorubicin
alone (45.8 ± 3.8% vs. 69.4 ± 7%, respectively, p<0.01, Figure
5).
Mdivi-1 protects against doxorubicin-induced
depolarisation and hypercontracture of cardiac
myocytes
Opening of the mitochondrial permeability transition is found
to be involved in doxorubicin induced cardiotoxicity [29,32].
Figure 6a shows the effects of drug treatment on the time taken
to the depolarisation of the cardiac myocytes following
persistent oxidative stress. Doxorubicin-treated cells
depolarised significantly faster (p<0.05) as compared to
vehicle-treated cells (189.2 ± 7.1%s vs. 253.6 ± 5.8s,
respectively, Figure 6a), while co-treatment of doxorubicin with
mdivi-1 significantly attenuated the observed effects of
doxorubicin alone (317 ± 7s vs. 189.2 ± 7.1s, p<0.001,
respectively, Figure 6a). Doxorubicin treatment caused a
significant (p<0.01) reduction in the time taken to
hypercontracture of cardiac myocytes as compared to cells
treated with vehicle control (472 ± 14.2s vs. 667.7 ± 15.3s;
Figure 6b). Treatment with mdivi-1 alone significantly (p<0.001)
delayed the time taken to hypercontracture as compared to
control (921.4 ± 38.6s vs. 667.7 ± 15.3s, respectively, Figure
6b). Interestingly, the combination of doxorubicin with mdivi-1
reduced (p<0.001) the effects of doxorubicin alone on the time
taken to hypercontracture (804.7 ± 16.7 vs. 472 ± 14.2s,
respectively, Figure 6b).
Effect of mdivi-1 on doxorubicin-induced effects on Erk
1/2 and Akt signalling protein levels
Western blot analysis upon treating Langendorff hearts with
doxorubicin or mdivi-1 (alone and in combination showed that
doxorubicin treatment caused approximately 88% increase in
the levels p-Akt as compared to vehicle treated samples. Co-
treatment of doxorubicin with mdivi-1 and administration of
mdivi-1 alone also caused increase in the p-Akt levels as
compared to control (268% and 146%, respectively, Figure 7a).
Furthermore, co-treatment of doxorubicin with mdivi-1 also
produced significance when compared with doxorubicin alone
(268 ± 21% vs 188 ± 7%, respectively, Figure 7a). We also
Doxorubicin-Induced Mitochondrial Fission
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Figure 2.  The effects of Doxorubicin (Dox), Mdivi-1 and the co-administration of Dox + Mdivi-1 on the haemodynamics of
the heart.  The hearts underwent 20 minutes of stabilization followed by 120 minutes perfusion in the presence absence of drugs
(alone and in combination).The effects of drug treatment on left ventricular developed pressure, b) heart rate and c) coronary flow
as a percentage of the mean stabilization period. *p<0.05 vs. time matched control, **<0.01 vs. time matched control, #p<0.05 vs.
time matched doxorubicin. n= 6-8.
doi: 10.1371/journal.pone.0077713.g002
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investigated the effects of drug treatment on Erk 1/2
phosphorylation and found that doxorubicin alone caused a
significant increase (by 34%) in the levels of Erk 1/2
phosphorylation whereas treatment with mdivi-1 alone did not
have any effect on Erk 1/2 levels. Interestingly, co-treatment of
doxorubicin with mdivi-1 significantly attenuated the increase in
p-Erk 1/2 observed with doxorubicin alone (104 ± 7% vs. 134 ±
8.9%, p<0.05, respectively, Figure 7b).
Effect of mdivi-1 on doxorubicin-induced effects on
phospho-Drp1 and phospho-p53 levels
Flow cytometric analysis of phospho-Drp1 (p-Drp1) levels
showed that treatment with doxorubicin (1µM) caused a
significant (p<0.01) up regulation in the levels of p-Drp1 when
compared to control (165.7 ± 16.8 % vs. 100 ± 7.5 %,
respectively, Figure 8a). Interestingly, co-treatment of
doxorubicin with mdivi-1 significantly (p<0.01) abrogated the
increase in p-p-Drp1 levels caused by doxorubicin alone (116.1
± 18.1% vs. 165.7 ± 16.8 %, respectively, Figure 8a).
Treatment with mdivi-1 alone did not cause a significant
change in the levels of p-Drp1 when compared to control
(101.7 ± 6.3% vs. 100 ± 7.5%, respectively, Figure 8a).
Treatment with doxorubicin also caused a significant (p<0.001)
increase in the levels of phopho-p53 (p-p53) when compared to
control (198 ± 17.8% vs 100 ± 14.4%, respectively, Figure 8b).
Co-treatment of doxorubicin with mdivi-1 prevented (p<0.001)
the increase in the p-p53 levels caused by doxorubicin alone
(92.9 ± 6.9% vs 198 ± 17.8%, respectively, Figure 8b).
Treatment with mdivi-1 alone did not have an effect on the
levels of p-p53 when compared to control (97.3 ± 9.1% vs 100
± 7.5%, respectively, Figure 8b).
Co-incubation of mdivi-1 with doxorubicin does not
alter the cytotoxicity of doxorubicin against leukaemic
HL60 cells
The colorimetric MTT assay demonstrated as expected that
doxorubicin reduced the viability of HL60 cells by 33% as
compared to the non-treated controls (p<0.01). Co-
administration of doxorubicin with mdivi-1 did not alter the anti-
cancer activities of doxorubicin alone. Similarly, mdivi-1 alone
Figure 3.  The effects of Dox, Mdivi-1 and the co-administration of Dox with Mdivi-1 on the infarct to risk ratios in the
isolated heart Langendorff model.  ***p<0.001 vs. control, #p<0.05 vs. doxorubicin, ###p<0.001 vs. doxorubicin n= 6-8.
doi: 10.1371/journal.pone.0077713.g003
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Figure 4.  The effects of Doxorubicin (Dox), Mdivi-1 and the co-administration of Dox + Mdivi-1 on the haemodynamics of
the heart during ischaemia and reperfusion.  The hearts underwent 20 minutes of stabilization, 35 of ischaemia and 120 minutes
of reperfusion, drugs are administered throughout reperfusion period. a) The effects of drug treatment on heart rate, b) left
ventricular developed pressure (LVDP) and c) coronary flow as a percentage of the mean stabilization period. *p<0.05 vs. time
matched IR control, **<0.01 vs. time matched IR control. n= 6-8. IR, ischaemia/reperfusion; Dox, doxorubicin.
doi: 10.1371/journal.pone.0077713.g004
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did not have any effects on the cell viability of the cells as
compared to control (Figure 9).
Discussion
Doxorubicin treatment is known to cause cardiovascular
toxicity due to the generation of reactive oxygen species [5]
and calcium overload [33]. Previous research has
demonstrated that doxorubicin induced toxicity affects
mitochondrial bioenergetics and causes mitochondrial
fragmentation [17]. We demonstrate that doxorubicin induced
dysfunction on the haemodynamic parameters of the hearts are
reversed by mdivi-1, a relatively specific inhibitor of
mitochondrial division.
Doxorubicin induced effects of cardiac function has been
reported in in vivo and in vitro studies. Doxorubicin has
previously been found to reduce both left ventricular developed
pressure and heart rate, also shown in this study [15,34,35].
Interestingly, the presented data show that doxorubicin
treatment in the naïve hearts caused a drop in the heart rate
readings as opposed to its effects in conditions of ischaemia
and reperfusion injury where no significant decrease in the
heart rate values were recorded. One possible explanation for
this effect could be the level of oxygen, previously published
work has indicated that doxorubicin-induced decrease in the
heart rate was more prominent when the heart were perfused
with 95% oxygen as compared to 20% oxygen [34]. We also
show that co-treatment with mdivi-1 abrogated the detrimental
effects of doxorubicin on left ventricular developed pressure.
Interestingly, treatment with mdivi-1 was shown to ameliorate
left ventricular dysfunction caused by pressure overload heart
failure as assessed by left ventricular chamber diameter and
fractional shortening [27]. Mitochondrial fragmentation is
proposed to be a major player in exacerbation of heart failure,
inhibition of fragmentation is therefore thought to confer
cardioprotection [27]. Recent research has indicated that
mitochondrial dynamics play a crucial role in cell physiology
and growing evidence suggests that a balance between
Figure 5.  The effects of Dox, Mdivi-1 and the co-administration of Dox and Mdivi-1 on the infarct to risk ratios in the whole
heart Langendorff model of ischaemia/reperfusion injury.  **p<0.001 vs. IR control and ##p<0.01 vs. doxorubicin. n= 6-8. IR,
ischaemia/reperfusion; Dox, doxorubicin.
doi: 10.1371/journal.pone.0077713.g005
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mitochondrial fission and fusion plays a vital role in pathological
conditions [23,36,37]. Studies have also shown that
mitochondrial oxidative stress, which is also induced by
doxorubicin treatment [1,5], leads to fragmentation of the
mitochondria, which were attenuated with reactive oxygen
species scavengers [38]. Mitochondrial fragmentation has been
found to mediate cellular function and apoptosis [37,39].
Mdivi-1 has been suggested to have therapeutic potential for a
variety of diseases such as stroke, myocardial infarction and
neurodegenerative disorders [23,26,40]. In the current study,
flow cytometric analyses of p-Drp1 levels show a significant up
regulation of p-Drp1 levels following treatment with doxorubicin,
which was prevented when doxorubicin was co-administered
with mdivi-1. Elevated levels of mitochondrial fission proteins
have been reported in response to ceramide and doxorubicin
induced toxicity [17]. It has been demonstrated that mdivi-1
inhibits GTPase activity by blocking self-assembly of Drp1,
preventing mitochondrial fission [40]. It has been postulated
that doxorubicin induced cardiotoxicity involves fragmentation
of the mitochondria. A recent study has shown that doxorubicin
treatment leads to an increase in GTPases that are found to
govern mitochondrial fission and fusion [41]. Imbalance in
mitochondrial dynamics has been found to play a critical role in
the pathophysiology of the failing heart [42]. Therefore,
modulation of mitochondrial fission and fusion machinery could
therefore compensate for the detrimental effects of doxorubicin
on mitochondrial bioenergetics [17,41,43].
In the current study we demonstrate for the first time the
effects of mitochondrial division inhibition (mdivi-1) on
doxorubicin induced cardiotoxicity in naïve and in the
conditions of ischaemia and reperfusion injury. We
demonstrate that co-administration of mdivi-1 with doxorubicin
significantly reduced doxorubicin-induced myocardial
dysfunction and infarction in both conditions. Whether
doxorubicin-induced effect on coronary flow was a direct effect
on coronary endothelial cells or secondary to the injury of
cardiac myocytes was not further investigated. It is critical to
investigate therapeutic potential of anti-cancer compounds in
stressed conditions such as ischaemia or reperfusion injury, as
cancer and cardiovascular diseases are likely to co-exist in
patients. It has also been shown that anti-cancer drugs can
lead to or exacerbate the risk of cardiomyopathy when baseline
heart diseases are taken into account [12]. An analysis of 5-
year cancer survivors has found that a huge number of cancer
patients on anthracyclines die from cardiac related causes [44].
They also showed that cancer treatments in childhood cancers
increased the risk of congestive heart failure 15 fold compared
to the non-treated [44,45]. Furthermore, we have recently
shown that doxorubicin administration at the time of reperfusion
exacerbates ischaemia and reperfusion injury, which was
abrogated with co-treated with mPTP blocker cyclosporin A
[29]. Hence, cancer therapeutics may prove to exacerbate
underlying cardiovascular diseases, as we have shown in this
study, and it is important to assess potential adjunct therapies
in pathological conditions as well as in naïve conditions.
Recently, experimental evidence has highlighted multiple
beneficial effects of mdivi-1 treatment by specific and non-
specific actions by reducing ischaemia reperfusion injury [26]
and pressure induced heart failure [27]. Mdivi-1 treatment is
also found to directly inhibit the rapidly activating delayed-
rectifier K+ currents in HL-1 cells in a concentration dependent
manner [46]. The protective effects of mdivi-1 in doxorubicin-
induced cardiotoxic effects observed in this study could be a
direct effect on mitochondrial fragmentation, which is found to
occur simultaneously with the release of cytochrome c [39]. It
has also been noted that Drp1 inhibition interferes with the
apoptotic process, without completely inhibiting cell death [47].
Direct effects of mdivi-1 on cardiac myocyte mitochondria were
Figure 6.  The effects of doxorubicin, Mdivi-1 and the co-treatment of doxorubicin and Mdivi-1 on the time taken to (A)
depolarisation and (B) hypercontracture of the rat cardiac myocytes under the conditions of sustained oxidative
stress.  *p<0.05 vs. control, **p<0.01 vs. Control, ***p<0.001 vs. Control and ###p<0.001 vs. doxorubicin, n=6 (each n comprising
of 20±5 cells).
doi: 10.1371/journal.pone.0077713.g006
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Figure 7.  The effects of Dox, Mdivi-1 and co-treatment on the levels of phosphorylated (A) Akt and (B) Erk 1/2.  (C)
Representative blots showing p-Akt, total Akt, p-Erk 1/2 and total Erk 1/2. **p>0.01 vs. control , ***p<0.001 vs. control, #p<0.01 vs.
doxorubicin and ###p<0.001 vs doxorubicin.
doi: 10.1371/journal.pone.0077713.g007
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shown previously in myocardial ischaemia reperfusion injury
[26]. Our results show that doxorubicin treatment caused rapid
depolarisation and hypercontraction of cardiac myocytes as
compared to non-treatment following persistent oxidative
stress, a similar effect of oxidative stress on mitochondrial
energetics and permeability transition has previously been
reported [17,41,48,49]. We also show that mdivi-1 caused a
delay in depolarisation and hypercontraction, confirming
previous reports on the protective effects of mdivi-1 on ROS
induced mPTP opening [26]. Interestingly, co-treatment of
doxorubicin with mdivi-1 protected against doxorubicin-induced
effects on depolarisation and hypercontraction. These findings
further confirm the involvement of mitochondrial fission in
doxorubicin-induced cardiotoxicity and suggest that
pharmacological modulating mitochondrial fission may have
cardioprotective effects, which could also directly affect the
mPTP [48,49].
Western blot analysis were carried out to investigate the
effects of drug-treatment on the levels of survival kinases Akt
and Erk 1/2 as well as to investigate whether the protective
mdivi-1 against the damaging effects of doxorubicin involve
these pathways. We observed that treatment with doxorubicin
increased the levels of the survival proteins, p-Erk 1/2 and p-
Akt. Doxorubicin-induced increase in the levels of Akt could
either be a direct effect of doxorubicin on the cardiac myocytes
in the heart or an indirect effect of the heart that is initiated in
order to protect against the damaging effects of doxorubicin.
Previous studies have indicated this effect of doxorubicin
treatment on survival proteins and it has been suggested that it
may serve as an endogenous protective effect of the heart to
protect against the toxic effects of doxorubicin [50–52].
Figure 8.  The effects of Dox, Mdivi-1 and co-treatment on the levels of (A) phospho-Drp1 and (B) phospho-p53 with the
representative flow cytometry traces of (C) phospho-Drp1 and (D) phospho-p53.  **p>0.01 vs. control, ***p>0.01 vs. control,
##p<0.01 vs. doxorubicin and ###p<0.01 vs. doxorubicin.
doi: 10.1371/journal.pone.0077713.g008
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Downstream effectors of Akt and Erk converge to the
mitochondria and initiate a protective response [53]. There is
additional evidence that coronary delivery of constitutively
active form of Akt1 gene protects the heart against doxorubicin-
induced chronic heart failure by improving cardiac performance
[54]. We postulate that the increase in the pro-survival proteins
observed in this study serves as an innate mechanism of the
heart to protect against the damaging effects of doxorubicin.
We also show increased p-Akt levels when treated with mdivi-1
alone and a further increase when treated with the combination
of mdivi-1 and doxorubicin. A link between Akt pathway and the
mitochondrial fusion and fission mechanism has been
suggested previously [23]. It is believed that increase in Akt
phosphorylation promotes mitochondrial fusion, which is
considered to lead to its cardioprotective effects. It has also
been reported that compounds which offer cardio-protection
such as insulin or anti-oxidants prevent ischaemia induced
fragmentation and produces elongated mitochondria [55]. It has
also been speculated that the cytokine erythropoietin induces
mitochondrial fusion by activating Akt [23]. However, a
downstream effector of Akt, protein kinase G (PKG), has been
reported to phosphorylate and inhibit the pro-fission activity of
Drp1. A recent study reported increase in the levels insulin
stimulated Akt phosphorylation when also treated with mdivi-1
[56]. Further investigations are needed to establish whether
mdivi-1 treatment causes a direct effect on Akt
phosphorylation. We speculate that the huge increase
observed in Akt phosphorylation when co-treated with
doxorubicin and mdivi-1, is due to the dual effect of doxorubicin
(innate response of the heart) and a direct effect of mdivi-1 on
Akt phosphorylation causing a further increase. Previously, we
reported a significant increase in the levels of p-Akt following
doxorubicin-treatment in conditions of ischaemia and
reperfusion injury, which was partially blocked when co-
administered with cyclosporin A as well as providing protection
against the toxic effects of doxorubicin [29]. Further studies are
required to investigate the exact role of doxorubicin-induced
toxicity and the protection there from with adjunct therapy on
Akt phosphorylation. Studies have also reported a link between
ROS generation, mitochondrial morphology and Erk 1/2
Figure 9.  The effects of Dox, Mdivi-1 and co-treatment on the MTT reductase activity as compared to control on HL60
cancer cells.  **p>0.01 vs. control, ##p<0.01 vs. doxorubicin.
doi: 10.1371/journal.pone.0077713.g009
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signalling in the regulation of insulin signalling pathway.
Obesity induced ROS appeared to increase the levels of Erk
1/2 phosphorylation, which were reversed when treated with
mdivi-1 [56]. A similar effect is also seen in our data showing
that co-treatment with mdivi-1 reverses doxorubicin induced
increase in Erk 1/2 levels. Furthermore, it has been reported
that doxorubicin-induced involves Erk/p53 transduction
pathway [57]. Treatment of H9c2 and cardiac myocytes with
doxorubicin caused an increase in the levels of p53 which were
preceded by activation and nuclear translocation of Erk 1/2
[57]. They also showed that inhibition of Erk 1/2 with U-0126
prevented activation and nuclear translocation of both Erk 1/2
and p53 whilst inhibition of p53 with pifithrin-α only prevented
doxorubicin-induced changes in p53 [57]. In the current study
we show an increase in the levels of p53 and Erk 1/2 following
treatment with doxorubicin. Interestingly, co-administration of
doxorubicin with mdivi-1, which prevented detrimental effects of
doxorubicin in the Langendorff and oxidative stress model and
reduced the levels of p-Drp1, also prevented the increase in
the levels of both p53 and Erk 1/2. Further studies are required
to identify the specific role of Erk 1/2 and Akt activation using
their specific inhibitors and the intracellular signalling pathway
associate with the protective effect mdivi-1.
Furthermore, we show that co-treatment with mdivi-1 does
not interfere with the anti-cancer properties of doxorubicin as
assessed by MTT assay using HL60 cells (Figure 9). It is
imperative to assess the effects of adjunct therapies, aiming to
reduce the cardiotoxic effect, on the anti-tumour effects. Many
cardioprotective strategies fail to demonstrate beneficial effects
in clinical or in vivo settings as they interfere or reduce with the
anti-cancer effects and thereby reduce the clinical utility [14].
Collectively, our data show that co-treatment with the
mitochondrial fission inhibitor mdivi-1 can ameliorate the
cardiotoxic effects of doxorubicin without affecting its anti-
cancer properties. These finding warrant further investigations
in the relevant animal models of cancer.
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